Nanoligent Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$14.1M
- Investors
-
12
Nanoligent General Information
Description
Developer of nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer. The company utilizes protein engineering and nanobiotechnology to create self-assembling protein nanoparticles that selectively kill metastatic cells, enabling medical practitioners to improve patients' lives by designing medicines that target the cells affected by the disease through treatments more effective than classical drugs.
Contact Information
Website
www.nanoligent.comCorporate Office
- Eureka Building,Avenue de Can Doménech s / n
- UAB Campus, Bellaterra
- 08193 Barcelona
- Spain
Corporate Office
- Eureka Building,Avenue de Can Doménech s / n
- UAB Campus, Bellaterra
- 08193 Barcelona
- Spain
Nanoligent Timeline
Nanoligent Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 06-Oct-2025 | $14.1M | Completed | Pre-Clinical Trials | ||
| 6. Grant | 19-Jun-2025 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 21-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 27-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 3. Equity Crowdfunding | 03-Feb-2022 | Cancelled | Pre-Clinical Trials | |||
| 2. Seed Round | 03-Feb-2022 | $1.13M | $1.13M | Completed | Pre-Clinical Trials | |
| 1. Grant | 13-Dec-2018 | $1.7K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nanoligent Patents
Nanoligent Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7810873-B2 | Nidogen-based scaffold proteins and therapeutic nanocomplexes | Active | 26-Dec-2019 | ||
| JP-2023509004-A | Nidogen-based scaffold proteins and therapeutic nanocomposites | Active | 26-Dec-2019 | ||
| JP-2026065032-A | Nidogen-based scaffold proteins and therapeutic nanoconjugates | Pending | 26-Dec-2019 | ||
| AU-2021204681-A1 | Scaffold proteins and therapeutic nanoconjugates based on nidogen | Pending | 26-Dec-2019 | ||
| CA-3166013-A1 | Scaffold proteins and therapeutic nanoconjugates based on nidogen | Pending | 26-Dec-2019 | C07K14/78 |
Nanoligent Signals
Nanoligent Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Clave (Pamplona) | Venture Capital | Minority | ||
| INNVIERTE SICC | Government | Minority | ||
| Inveready Asset Management | Venture Capital | Minority | ||
| University of Alabama at Birmingham | University | |||
| Archimedes Accelerator | Accelerator/Incubator | Minority |
Nanoligent FAQs
-
When was Nanoligent founded?
Nanoligent was founded in 2017.
-
Where is Nanoligent headquartered?
Nanoligent is headquartered in Barcelona, Spain.
-
What is the size of Nanoligent?
Nanoligent has 9 total employees.
-
What industry is Nanoligent in?
Nanoligent’s primary industry is Drug Delivery.
-
Is Nanoligent a private or public company?
Nanoligent is a Private company.
-
What is Nanoligent’s current revenue?
The current revenue for Nanoligent is .
-
How much funding has Nanoligent raised over time?
Nanoligent has raised $18M.
-
Who are Nanoligent’s investors?
Clave (Pamplona), INNVIERTE SICC, Inveready Asset Management, University of Alabama at Birmingham, and Archimedes Accelerator are 5 of 12 investors who have invested in Nanoligent.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process